What the FDA labels say about taking them together
Adalimumab and adalimumab-aacf
Adalimumab's FDA label (Adalimumab-Aacf) of January 8, 2026 names adalimumab-aacf in its boxed warning section, and adalimumab-aacf's label names adalimumab too. The adalimumab label: “Increased risk of serious infection. Live vaccines: Avoid use with Adalimumab-aacf.”
Check it at the source: the adalimumab FDA label on DailyMed (effective October 21, 2025); the adalimumab-aacf FDA label on DailyMed (effective January 30, 2026, Fresenius Kabi USA, LLC).
What does the adalimumab label say about adalimumab-aacf?
Adalimumab-Aacf label (Fresenius Kabi USA, LLC, January 8, 2026), boxed warningSERIOUS INFECTIONS Patients treated with adalimumab products including Adalimumab-aacf are at increased risk for developing serious infections that may lead to hospitalization or death [see Warnings and Precautions ( 5.1 )].
Adalimumab-Aacf label (Fresenius Kabi USA, LLC, January 8, 2026), drug interactionsIncreased risk of serious infection. ( 5.1 , 5.7 , 7.2 ) Live vaccines: Avoid use with Adalimumab-aacf.
Adalimumab-Aacf label (Fresenius Kabi USA, LLC, January 8, 2026), warnings and precautionsIf an infection develops, monitor carefully, and stop Adalimumab-aacf if infection becomes serious. ( 5.1 ) Invasive fungal infections:
Source: FDA drug label (Adalimumab-Aacf, BLA761255), Fresenius Kabi USA, LLC, effective January 8, 2026 (SPL set 2488b0bc-7b8f-4cc8-91ea-48e7ea5e8915), via openFDA
Source: FDA drug label (Adalimumab), Sandoz Inc, effective October 21, 2025 (SPL set 3468792f-63ef-4916-8ed1-8214f327d9dd), via openFDA; the full label on DailyMed
What does the adalimumab-aacf label say about adalimumab?
Adalimumab-aacf label, boxed warningSERIOUS INFECTIONS Patients treated with adalimumab products including IDACIO are at increased risk for developing serious infections that may lead to hospitalization or death [see Warnings and Precautions ( 5.1 )].
Adalimumab-aacf label, drug interactionsAlthough MTX reduced the apparent adalimumab clearance, the data do not suggest the need for dose adjustment of either IDACIO or MTX [see Clinical Pharmacology ( 12.3 )].
Adalimumab-aacf label, warnings and precautionsPatients treated with adalimumab products including IDACIO are at increased risk for developing serious infections involving various organ systems and sites that may lead to hospitalization or death.
Source: FDA drug label (Idacio), Fresenius Kabi USA, LLC, effective January 30, 2026 (SPL set 43de75ac-1a37-4609-9edd-68bda2448a47), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Adalimumab | Adalimumab-aacf | |
|---|---|---|
| Labeled for | Rheumatoid arthritis, Crohn's disease and ulcerative colitis, Psoriasis | Rheumatoid arthritis, Crohn's disease and ulcerative colitis, Psoriasis |
| Boxed warning | Yes | Yes |
| Pharmacy cost (NADAC) | $1,587.82 per mL 40 mg/0.4 mL | n/a |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once